Marco Caremi

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Ducati Motor Holding SpA engages in the design and manufacture of motorcycles. The firm also offers motorcycle accessories such as chassis and brake systems, electric and electronic components exhaust systems, fiberglass and plastic fibers, garage accessories, and specialty materials. The company was founded by Adriano Ducati and Marcello Ducati in 1926 and is headquartered in Bologna, Italy.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Luigi Lavazza SpA manufactures and distributes coffee. Its products include coffee capsules; instant coffee; compatible capsules; and coffee blends, beans, and pods. It also offers accessories including espresso cups and spoons, mugs, capsule holder, sweet bites, frothers, coffee maker, and descaling. The company was founded by Luigi Lavazza in 1895 and is headquartered in Turin, Italy.

Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France.

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

Dipylon Medical AB engages in the research and development of pharmaceutical products. The firm manufactures and sells products, materials and general medical instruments. It offers metabolic patient monitoring system. The company was founded on April 3, 1984 and is headquartered in Solna, Sweden.

May & Baker Ltd. manufactures pharmaceutical products. The company is headquartered in Guildford, GB.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Part of MiCo IVD Holdings, LLC, Fiomi Diagnostics AB is a Swedish company that develops, manufactures, and markets diagnostic test kits. The private company is based in Uppsala, Sweden. Fiomi Diagnostics was acquired by Trinity Biotech Plc on March 01, 2012 for $13.12 million.

Part of Getinge AB, Eirus Medical AB is a Swedish company that provides medical technology development services. The private company is based in Solna, Sweden. Eirus Medical was acquired by Getinge AB from Dipylon Medical AB on June 30, 2012 for $0.72 million.

Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013.

Ginolis AB develops components in polymer by first producing the parts in original through different methods for sculpting silicon and glass wafers. These originals are transferred to molds in which the final components are manufactured through time-effective and thus economical favorable polymer replication processes. The polymers themselves, compared with silicon micromechanics, could also add material property advantages with the vast variety of materials available. They can with this platform serve many different fields all with the same need of precision and complexity. Ginolis AB has the skill and experience to integrate different functions onto the very same chip in order to achieve functions that, if they are at all possible to manufacture with traditional technique, needs several parts assembled to mechanical systems with higher cost for the parts as a consequence. These functions include nano- and microfludic channels, surface chemistry, electrical wave guides and connectors, refractive and diffractive micro-optics.

Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands.

Part of Oncopeptides AB, Oncopeptides, Inc. is a private company committed to developing therapies for difficult-to-treat hematological diseases. The company is based in Waltham, MA. Oncopeptides strives to bring hope to patients through science and innovation, and is dedicated to bringing forward new and meaningful treatment options. The company is inspired by the perseverance of patients, caregivers, and healthcare providers in their fight against cancer. Oncopeptides' focus is on the development of therapies that can make a difference in the lives of those affected by hematological diseases.